文献速递免疫规划传染病防控与疫情报告

优化鞭毛蛋白增强SARS-CoV-2病毒样颗粒疫苗的系统与黏膜免疫应答

Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
PubMed 文献 · Vaccine · 2026-05-28

本研究在Sf9细胞中制备SARS-CoV-2病毒样颗粒(VLP),并在BALB/c小鼠中经鼻内免疫VLP联合全长鞭毛蛋白(FliC)或其截短变体NCFliC。结果显示两种佐剂均显著增强VLP特异性体液、黏膜和细胞免疫,且NCFliC自身免疫原性低于FliC,提示NCFliC是有前景的黏膜佐剂。

要点

  • NCFliC保留强TLR5佐剂活性且自身免疫原性低于FliC。
  • VLP+NCFliC经鼻免疫可增强系统IgG、黏膜IgA和Th1应答。
  • NCFliC与FliC在增强VLP免疫应答方面佐剂效力无显著差异。

核心结论

  • NCFliC保留强佐剂活性且内在免疫原性降低,经鼻免疫VLP+NCFliC可在小鼠中诱导强系统与黏膜免疫。

研究设计与样本

  • 在Sf9细胞中通过杆状病毒表达系统表达SARS-CoV-2 S、E、M蛋白制备自组装VLP。
  • 表达纯化全长沙门氏菌鞭毛蛋白FliC及其截短变体NCFliC(ΔD2/D3),并在HEK293-mTLR5细胞中验证TLR5配体活性。
  • BALB/c小鼠经鼻内免疫VLP单独或联合FliC/NCFliC,通过ELISA、脾细胞增殖实验和细胞因子检测评估体液、黏膜和细胞免疫应答。

主要发现

  • 制备的VLP(约80 nm)具有天然结构和特异性ACE2结合活性。
  • FliC和NCFliC均保留强TLR5配体活性,激活NF-κB并促进IL-8分泌。
  • 经鼻免疫显示NCFliC和FliC均显著增强VLP特异性体液免疫(IgG)、Th1型应答(IgG2a/IFN-γ)、黏膜IgA(鼻洗液/支气管肺泡灌洗液)和脾细胞增殖,两者佐剂效力无显著差异。
  • 与FliC相比,NCFliC诱导的FliC特异性血清IgG、IgG亚类(IgG1、IgG2a)及鼻洗液和支气管肺泡灌洗液中IgA水平显著更低。

临床怎么用

  • NCFliC可作为SARS-CoV-2 VLP疫苗的候选黏膜佐剂,经鼻免疫策略可能同时诱导系统与黏膜免疫。

局限性

  • 研究仅在小鼠中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutates continuously, and current injectable vaccines induce limited mucosal immunity, while clinical subunit mucosal vaccines and safe adjuvants are lacking. Virus-like particles (VLPs) are promising vaccine candidates, and flagellin is a potential TLR5 agonist adjuvant, yet its high intrinsic antigenicity remains a challenge. METHODS: SARS-CoV-2 S, E, M proteins were expressed in Sf9 cells via the baculovirus expression system to prepare self-assembled VLPs. Full-length Salmonella flagellin (FliC) and its truncated variant NCFliC (ΔD2/D3) were expressed and purified. TLR5 ligand activity of FliC/NCFliC was verified in HEK293-mTLR5 cells. BALB/c mice were intranasally immunised with VLP alone or combined with FliC/NCFliC. The humoral, mucosal and cellular immune responses were evaluated by ELISA, splenocyte proliferation assay and cytokine detection assays. RESULTS: The prepared VLPs (≈80 nm) exhibited native structure and specific ACE2-binding activity. FliC and NCFliC both retained robust TLR5 ligand activity, activating NF-κB and promoting IL-8 secretion. Intranasal immunization showed NCFliC and FliC both significantly enhanced VLP-specific humoral immunity (IgG), Th1-type responses (IgG2a/IFN-γ), mucosal IgA (nasal/bronchoalveolar lavage fluid) and splenocyte proliferation, with no significant difference in adjuvant efficacy between them. Notably, compared with FliC, NCFliC induced significantly lower levels of FliC-specific serum IgG, IgG subclasses (IgG1, IgG2a), and IgA in nasal and bronchoalveolar lavage fluid. CONCLUSIONS: NCFliC retains potent adjuvant activity while having reduced intrinsic immunogenicity, and intranasal immunization with VLP + NCFliC elicits robust systemic and mucosal immunity in mice. NCFliC is a promising mucosal adjuvant for SARS-CoV-2 VLP vaccines, providing a potential strategy for developing next-generation anti-coronavirus mucosal vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Song L, He G, Cui Y, et al. Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines. Vaccine. 2026. PMID: 42208338. doi:10.1016/j.vaccine.2026.128767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。